Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adapalene + clindamycin is a fixed-dose topical combination medication used primarily for the treatment of acne vulgaris. Adapalene is a third-generation retinoid that acts as a retinoic acid receptor agonist; it modulates cellular differentiation and keratinization and exhibits anti-inflammatory properties by inhibiting keratinocyte proliferation and reducing inflammation. Clindamycin is an antibiotic in the lincosamide class that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of susceptible bacteria such as Cutibacterium acnes (formerly Propionibacterium acnes), thereby reducing bacterial colonization and inflammation in acne lesions. The combination targets both abnormal skin cell turnover and bacterial infection associated with acne[5][4][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + clindamycin.